Amikacin Sulfate
The sulfate salt form of amikacin, an aminoglycoside antibiotic administered by injection or inhalation to treat severe bacterial infections, particularly those caused by multidrug-resistant gram-negative organisms. Drug level monitoring is essential to ensure therapeutic efficacy while minimizing kidney and ear toxicity.
Peso molecular
781,8000 g/mol
TPSA
498,00 Ų
Áreas terapéuticas
Mecanismo de acción
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Estructura 2D
Cite this structure
Embed this structure
SMILES
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O
InChI
InChI=1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1
Molecular Formula
C22H47N5O21S2
HBD / HBA
17 / 25
Enlaces Rotables
10
Átomos Pesados
50
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The sulfate salt form of amikacin, an aminoglycoside antibiotic administered by injection or inhalation to treat severe bacterial infections, particularly those caused by multidrug-resistant gram-negative organisms. Drug level monitoring is essential to ensure therapeutic efficacy while minimizing kidney and ear toxicity.
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Yes, Amikacin Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4208954. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 38351. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amikacin-sulfate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amikacin-sulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amikacin-sulfate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amikacin-sulfate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amikacin-sulfate"></drugfyi-drug>